Granules India Share Price Target 2024, 2025, 2030, 2040

4.6/5 - (5 votes)

Granules India Share Price Forecast 2024, 2025, 2030, 2040

Granules India is a pharmaceutical company specializing in manufacturing and selling. The company has a diverse product portfolio with a strong presence in domestic and international markets for active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).In this blog post, we’ll discuss the fundamentals of Granules India, its strengths and weaknesses, and the share price prediction for 2023-2050.

Fundamentals of Granules India

Stock NameGranules India
Market Value7,762 Cr.
Book Value116

Granules India has a market capitalization of $1.6 billion and a price-to-earnings (PE) ratio of 17.6. The company’s fair value (FV) is estimated at INR 570.15. Granules India has reported an earnings per share (EPS) of INR 18.61 in the last fiscal year. The company has shown steady growth in the previous three years, with revenues increasing by 14.05% on average.

Granules India Share Holding Pattern

The shareholding pattern of Granules India is as follows:

ShareholderNo. of Shares% of Shareholding
Foreign FII10,997,17421.35%
Institutions DII11,425,4746.63%

Granules India’s Strengths and Weaknesses


  • Diverse product portfolio catering to different therapeutic segments
  • Strong presence in both domestic and international markets
  • Strategic collaborations with global pharmaceutical companies
  • Strong research and development capabilities


  • Dependence on a few key customers
  • Vulnerability to regulatory changes
  • Exposure to currency fluctuations
  • Low dividend payout ratio

Granules India Share Price Prediction 2023, 2024, 2025, 2028, 2030, and 2040

The share price of Granules India is projected to increase steadily over the years. The following table shows the predicted share price of Granules India for the years 2023, 2024, 2025, 2028, 2030, and 2040.

YearPredicted Share Price (INR)


In conclusion, Granules India is a strong player in the pharmaceutical industry with a diverse product portfolio and a strong presence in domestic and international markets. The company has shown steady growth in the last three years and is projected to continue growing. However, the company is also exposed to certain risks, such as dependence on key customers and vulnerability to regulatory changes. Overall, Granules India is a promising investment opportunity for those looking to invest in the pharmaceutical industry.

Leave a Reply